GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (NAS:XOMA) » Definitions » Equity-to-Asset
中文

XOMA (XOMA) Equity-to-Asset : 0.38 (As of Dec. 2023)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. XOMA's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $88.72 Mil. XOMA's Total Assets for the quarter that ended in Dec. 2023 was $234.30 Mil. Therefore, XOMA's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.38.

The historical rank and industry rank for XOMA's Equity-to-Asset or its related term are showing as below:

XOMA' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.65   Med: 0.34   Max: 0.88
Current: 0.38

During the past 13 years, the highest Equity to Asset Ratio of XOMA was 0.88. The lowest was -1.65. And the median was 0.34.

XOMA's Equity-to-Asset is ranked worse than
71.87% of 1564 companies
in the Biotechnology industry
Industry Median: 0.66 vs XOMA: 0.38

XOMA Equity-to-Asset Historical Data

The historical data trend for XOMA's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Equity-to-Asset Chart

XOMA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 0.69 0.85 0.88 0.38

XOMA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.88 0.86 0.88 0.85 0.38

Competitive Comparison of XOMA's Equity-to-Asset

For the Biotechnology subindustry, XOMA's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where XOMA's Equity-to-Asset falls into.



XOMA Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

XOMA's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=88.721/234.301
=0.38

XOMA's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=88.721/234.301
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XOMA  (NAS:XOMA) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


XOMA Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of XOMA's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA (XOMA) Business Description

Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Executives
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Thomas M. Burns officer: Chief Financial Officer 2910 SEVENTH STREET, BERKELEY CA 94710
James R Neal officer: VP Business Development 2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman director C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian director, officer: Director and CEO ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Matthew D Perry director, other: See Explanation of Responses ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104

XOMA (XOMA) Headlines

From GuruFocus

XOMA Declares Quarterly Preferred Stock Dividends

By sperokesalga sperokesalga 03-21-2023

XOMA Declares Quarterly Preferred Stock Dividends

By Tiesvg Tiesvg 12-22-2022

XOMA Declares Quarterly Preferred Stock Dividends

By GuruFocusNews GuruFocusNews 06-30-2022

XOMA to Present at 43rd Annual Cowen Health Care Conference

By sperokesalga sperokesalga 02-28-2023

XOMA to Present at H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 05-27-2022

XOMA to Present at H.C. Wainwright Global Investment Conference

By GuruFocusNews GuruFocusNews 07-06-2022